Imaging solutions are now available for in vivo study, you can understand your biology of interest as it functions in normal physiological context. With the combination of instrumentation and agents we provide you the ability to capture quantitative datasets for a whole range of application areas.
PerkinElmer's proprietary FMT technology (Fluorescence Molecular Tomography) provides non-invasive, whole body, deep tissue imaging in small animal models to generate 3D, information-rich results. These systems are used for research in oncology as well as inflammatory, pulmonary, cardiovascular and skeletal disease. Biological targets and pathways can be monitored and quantified in real time - giving a deeper understanding of the biology underlying disease mechanisms and therapeutic response.
Successful development of fluorescence agents for in vivo imaging depends on an understanding of biochemistry, cell biology and physiology, combined with knowledge of how to apply optimized chemistries. By leveraging in-house expertise and collaborating with key academic and pharmaceutical partners, PerkinElmer integrates chemistry, biology, and pharmacology to drive the development of fluorescence agents from initial concepts into validated products and applications. This approach enables key pharmacokinetic and delivery barriers in vivo to be overcome while taking advantage of biological and chemical amplification strategies whenever possible to optimize performance.
The agent portfolio is made up of three general classes : (1) Activatable agents which alter their fluorescence profiles in vivo to provide molecular and functional information in real time; (2) Targeted agents which pinpoint specific areas of interest and (3) Vascular agents which enable the monitoring of blood vessels and observation of phenomena such as blood leakage in tumors or inflamed regions and angiogenesis. These agents enable scientists not only to detect and monitor biology, but also to measure and accurately quantify biological mechanisms and therapeutic responses deep within the body non-invasively and in real time.
Images reflect in vitro-in vivo MMP biomarker readouts in HT-29 tumor lines, including (top left) HT-29 cells incubated with MMPSense 680; (right) quantitative HT-29 MMP activity in tumors imaged with MMPSense 680 and the FMT 2500 quantitative fluorescence tomography system, and (bottom left) MMPSense activity in ex vivo HT-29 tumor sections.